[go: up one dir, main page]

MX2010008423A - Tratamiento de infecciones microbianas. - Google Patents

Tratamiento de infecciones microbianas.

Info

Publication number
MX2010008423A
MX2010008423A MX2010008423A MX2010008423A MX2010008423A MX 2010008423 A MX2010008423 A MX 2010008423A MX 2010008423 A MX2010008423 A MX 2010008423A MX 2010008423 A MX2010008423 A MX 2010008423A MX 2010008423 A MX2010008423 A MX 2010008423A
Authority
MX
Mexico
Prior art keywords
treatment
microbial infections
directed
mscramm
present
Prior art date
Application number
MX2010008423A
Other languages
English (en)
Inventor
Timothy Foster
Judy Higgins
Elisabeth Josefsson
Joan Geoghegan
Andrej Tarowski
Original Assignee
Trinity College Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40512496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010008423(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0801768.3A external-priority patent/GB0801768D0/en
Application filed by Trinity College Dublin filed Critical Trinity College Dublin
Publication of MX2010008423A publication Critical patent/MX2010008423A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se dirige a mejorar vacunas de antígenos microbianos, composiciones farmacéuticas, composiciones inmunogénicas y anticuerpos y su uso en el tratamiento de infecciones microbianas, en particular las de origen bacteriano, incluyendo de origen estafilocócico. Idealmente, la presente invención se dirige a proteínas similares a MSCRAMM o MSCRAMM recombinantes estafilocócicas, o fragmento de las mismas, con reducción de unión a su ligando de huésped, para su uso en terapia.
MX2010008423A 2008-01-31 2009-01-29 Tratamiento de infecciones microbianas. MX2010008423A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IE20080070 2008-01-31
GBGB0801768.3A GB0801768D0 (en) 2008-01-31 2008-01-31 Treatment of microbial infections
PCT/EP2009/051033 WO2009095453A1 (en) 2008-01-31 2009-01-29 Treatment of microbial infections

Publications (1)

Publication Number Publication Date
MX2010008423A true MX2010008423A (es) 2010-09-22

Family

ID=40512496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008423A MX2010008423A (es) 2008-01-31 2009-01-29 Tratamiento de infecciones microbianas.

Country Status (22)

Country Link
US (3) US20110150918A1 (es)
EP (2) EP2244722B1 (es)
JP (1) JP5709527B2 (es)
KR (1) KR101739048B1 (es)
CN (1) CN101983067B (es)
AU (1) AU2009209598B2 (es)
BR (1) BRPI0906997A2 (es)
CA (1) CA2713241C (es)
CY (1) CY1118153T1 (es)
DK (1) DK2244722T3 (es)
EA (1) EA019516B1 (es)
ES (2) ES2960604T3 (es)
HR (1) HRP20161305T1 (es)
HU (1) HUE031614T2 (es)
LT (1) LT2244722T (es)
MX (1) MX2010008423A (es)
PL (1) PL2244722T3 (es)
PT (1) PT2244722T (es)
SG (1) SG188102A1 (es)
SI (1) SI2244722T1 (es)
WO (1) WO2009095453A1 (es)
ZA (1) ZA201005798B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1996231A4 (en) * 2006-02-22 2010-09-15 Texas A & M Univ Sys ANTIBODIES WITH STRONG EXPRESSED PUTATIVE ANTIGEN DETECTION OF CA-MRSA AND METHOD OF USE
MX2010008423A (es) 2008-01-31 2010-09-22 Trinity College Dublin Tratamiento de infecciones microbianas.
MX343111B (es) 2009-06-22 2016-10-25 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus.
CN102666583B (zh) 2009-07-15 2015-11-25 Aimm医疗股份公司 革兰氏阳性细菌特异性结合化合物
EP2453915B1 (en) 2009-07-16 2017-04-19 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Treatment of infections
GB0913680D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
WO2011045573A2 (en) 2009-10-15 2011-04-21 University Court Of The University Of Edinburgh Staphylococcal antigens
CN101843899B (zh) * 2010-05-24 2012-11-07 中国人民解放军第三军医大学 耐甲氧西林金黄色葡萄球菌（mrsa）重组多亚单位基因工程疫苗及其制备方法
EP2614074A1 (en) 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
WO2013159021A1 (en) * 2012-04-20 2013-10-24 The Texas A&M University System Engineered collagen binding mscramm with enhanced affinity for collagen
DK2917360T3 (da) * 2012-11-06 2020-03-30 Medimmune Llc Antistoffer mod S. aureus-overflade-determinanter
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
MX387007B (es) * 2014-12-10 2025-03-19 Glaxosmithkline Biologicals Sa Una composición inmunogénica para usarse en el tratamiento o prevención de la infección por staphylococcus aureus.
US9238090B1 (en) 2014-12-24 2016-01-19 Fettech, Llc Tissue-based compositions
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
GB201802339D0 (en) * 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
EP3618853B1 (en) * 2018-04-24 2020-09-09 Fibriant B.V. Fibrinogen gamma prime variants for use in treating an infection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008341A (en) * 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
CA2367830A1 (en) * 1999-04-28 2000-11-02 The Texas A & M University System Method of inhibiting leukocyte adhesion to fibrinogen
CA2351018A1 (en) * 2001-07-09 2003-01-09 Universite De Sherbrooke Dna vaccine against staphylococcus aureus
CA2562037A1 (en) 2004-05-21 2005-12-08 Wyeth Altered fibronectin-binding protein of staphylococcus aureus
MX2010008423A (es) 2008-01-31 2010-09-22 Trinity College Dublin Tratamiento de infecciones microbianas.

Also Published As

Publication number Publication date
KR20110000624A (ko) 2011-01-04
SG188102A1 (en) 2013-03-28
EA201001212A8 (ru) 2014-03-31
SI2244722T1 (sl) 2017-01-31
US20110150918A1 (en) 2011-06-23
ZA201005798B (en) 2013-01-30
PT2244722T (pt) 2016-11-04
AU2009209598A1 (en) 2009-08-06
US20150232518A1 (en) 2015-08-20
CA2713241A1 (en) 2009-08-06
KR101739048B1 (ko) 2017-05-23
LT2244722T (lt) 2016-10-25
US20170202943A1 (en) 2017-07-20
HRP20161305T1 (hr) 2017-01-27
ES2599953T3 (es) 2017-02-06
AU2009209598B2 (en) 2012-07-26
EP2244722A1 (en) 2010-11-03
EA201001212A1 (ru) 2011-02-28
EP2244722B1 (en) 2016-07-27
US11512118B2 (en) 2022-11-29
BRPI0906997A2 (pt) 2015-07-07
US9637525B2 (en) 2017-05-02
CY1118153T1 (el) 2017-06-28
EP3117832A1 (en) 2017-01-18
CA2713241C (en) 2022-10-04
HUE031614T2 (en) 2017-07-28
JP2011510952A (ja) 2011-04-07
EP3117832B1 (en) 2023-09-27
DK2244722T3 (en) 2016-11-14
CN101983067B (zh) 2017-07-11
JP5709527B2 (ja) 2015-04-30
CN101983067A (zh) 2011-03-02
EP3117832C0 (en) 2023-09-27
EA019516B1 (ru) 2014-04-30
WO2009095453A1 (en) 2009-08-06
ES2960604T3 (es) 2024-03-05
PL2244722T3 (pl) 2017-04-28

Similar Documents

Publication Publication Date Title
MX2010008423A (es) Tratamiento de infecciones microbianas.
NZ598524A (en) Therapeutic dll4 binding proteins
WO2013025834A3 (en) Compositions and methods related to antibodies to staphylococcal protein a
NZ602054A (en) Anti-nerve growth factor (ngf) antibody compositions
MY158560A (en) Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof
CY1119518T1 (el) Τροποποιημενα αντιγονα φυματιωσης
MX2010004482A (es) Anticuerpos anti-proteina g vsr.
MX2013004897A (es) Anticuerpos y composiciones anti-her3.
EP4434550A3 (en) Human antibody drug conjugates against tissue culture
MX2007003402A (es) Composicion inmunogena para su uso en vacunacion contra estafilococos.
GB2453491A (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
WO2008083239A3 (en) Compositions and methods for stimulating an immune response
EA201171494A1 (ru) Миметики белка smac
PT2126049E (pt) Anticorpos contra citomegalovírus humano (hcmv)
NZ616921A (en) Gram-positive bacteria specific binding compounds
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
MX2009008928A (es) Composiciones que comprenden conjugados de polisacaridos y su uso como vacunas.
WO2007100580A3 (en) Antibodies recognizing a highly expressed putative antigen of ca-mrsa and methods of use
BR112014023063A2 (pt) anticorpos que neutralizam rsv, mpv e pvm e usos dos mesmos
EP2463304A3 (en) Monoclonal antibodies that neutralize anthrax toxins
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
MX2013002718A (es) Composiciones de anticuerpo anti-vegfr-3.
WO2012122533A3 (en) Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
NZ720423A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
WO2009077744A3 (en) Vaccines for brucellosis

Legal Events

Date Code Title Description
FG Grant or registration